Revolutionizing Gastrointestinal Pathogen Detection:  A Breakthrough in Real-Time RT-PCR Assay CEO PCR25

552

A breakthrough in gastrointestinal pathogen detection through the development of a multiplex real-time polymerase chain reaction (PCR) assay: RT-PCR25

Revolutionizing Gastrointestinal Pathogen Detection:  A Breakthrough in Real-Time RT-PCR Assay CEO PCR25

Revolutionizing Gastrointestinal Pathogen Detection: 

A Breakthrough in Real-Time RT-PCR Assays 

 

Diarrhea PCR25: 1 test 1 price 25 infections 

 

A breakthrough in gastrointestinal pathogen detection through the development of a multiplex real-time polymerase chain reaction (PCR) assay called CEO PCR25

 

  • Diarrheal diseases are a significant global health concern caused by various pathogens.
  • Conventional diagnostic methods face issues like variability, low sensitivity, and long turnaround times.
  • Recent advancements in molecular diagnostics have led to the development of multiplex real-time PCR assays.

 

The RT-CEO PCR25


 

  • The ART-CEO PCR25 is a multiplex one-step real-time reverse transcription PCR assay.
  • It detects 6 viruses, 13 bacteria, and 6 parasites from a single stool specimen.
  • Developed using Seegene's MuDT™ technology, providing multiple Ct values for precise analysis.

 

Key Features and Advantages


 

  1. Broad Pathogen Coverage: Detects 25 different GI pathogens.
  2. Short Turnaround Time (TAT): Results available in 4 hours from sample extraction.
  3. Informative Data Output Provides individual Ct values for each pathogen for quantitative analysis.
  4. Automated Data Interpretation:** Equipped with Seegene Viewer for streamlined result analysis and reporting.

 

Implications for Clinical Practice


 

  • Rapid and accurate diagnosis of GI infections leading to timely interventions.
  • Detailed quantitative data facilitates better patient management and disease surveillance.

 

Conclusion


  • The CEO PCR25 offers a comprehensive and efficient solution for GI pathogen detection.
  • Its short turnaround time, informative data output, and automated interpretation contribute to improved patient care and public health outcomes.

 

Overall, this breakthrough represents a significant advancement in molecular diagnostics, addressing the limitations of traditional methods and enhancing patient care in managing gastrointestinal infections. 

 

Analytes

Panel 1

Panel 2Panel 3Panel 4

Virus

Bacteria (I)Bacteria (II)Parasite

Norovirus G I

Norovirus G II

Rotavirus

Adenovirus

Sapovirus

Internal Control (IC)

Campylobacter spp.

Clostridium difficile toxin B

Salmonella spp.

Shigella spp. / EIEC*

Vibrio spp.

Yersinia enterocolitica

Aeromonas spp.

Internal Control (IC)

Clostridium difficile hyperviralent

E coli O157

STEC* (stx1/2)

EPEC* (eaeA)

ETEC* (It/st)

EAEC* (aggR)

Internal Control (IC)

Giardia lamblia

Entamoeba histolytica

Blastocystis hominis

Dientamoeba fragilis

Cyclospora cayetanensis

Internal Control (IC)